Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OpACIN neoadjuvant/adjuvant ipilimumab + nivolumab feasibility study in resectable stage III melanoma
NL-OMON42085Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of ipilimumab and nivolumab in melanoma and cutaneous malignancy (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Change in neoantigen-specific T-cell response, Intratumoral T-cell response characterization and 1 more. Started Aug 2015; status: recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON42085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42085.